Company Filing History:
Years Active: 2024-2025
Title: Spencer Park - Innovator in Immunotherapy
Introduction
Spencer Park is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of immunotherapy, particularly through his innovative patents. With a total of 2 patents, his work focuses on advancing treatments for diseases such as cancer.
Latest Patents
One of Spencer's latest patents is titled "Codon-optimized nucleotide sequences encoding an AP-1 transcription factor." This patent discloses polynucleotides that comprise a nucleotide sequence encoding an AP-1 transcription factor, specifically c-Jun. The polynucleotides may include additional sequences encoding various functional domains, which can be utilized in cells, vectors, and pharmaceutical compositions aimed at treating diseases.
Another significant patent is the "ROR1 targeting chimeric antigen receptor." This invention relates to polynucleotides that encode a chimeric polypeptide, which includes a c-Jun polypeptide and a ROR1-binding protein. The patent also covers T cells expressing CARs that overexpress c-Jun, enhancing their properties and reducing exhaustion.
Career Highlights
Spencer Park is currently employed at Lyell Immunopharma, Inc., where he continues to push the boundaries of immunotherapy research. His work is instrumental in developing innovative solutions for complex medical challenges.
Collaborations
Spencer collaborates with talented individuals such as Queenie Vong and Blythe Sather, contributing to a dynamic research environment that fosters innovation.
Conclusion
Spencer Park's contributions to immunotherapy through his patents and collaborations highlight his role as a leading inventor in the field. His work is paving the way for new treatments that could significantly impact patient care.